Phosphoalkyl Polymer Drug Conjugates With Cleavable Targeting Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing targeted drug conjugates, particularly antibody-drug conjugates (ADCs), face challenges due to the complexity of the chemical linker between the antibody and drug, leading to difficulties in developing effective therapeutics with a large therapeutic index and sensitive discrimination between healthy and diseased tissues.
Innovation Solution
The development of polymeric biologically active compounds with biologically active moieties covalently linked by a linker, allowing for selective delivery to targets like tumor cells, optionally incorporating fluorescent and/or colored dyes, and including a targeting moiety for enhanced specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates use complex chemical linkers to connect antibody and drug, then the conjugate can achieve targeted delivery, but the development complexity increases and therapeutic index is reduced
Solution Approach 1:
The patent divides the conjugate into distinct modular components: a polymer backbone with multiple drug attachment sites, cleavable linker modules, and antibody conjugation sites. This segmentation allows independent optimization of each component and simplifies the overall development process while maintaining targeted delivery capability.
Solution Approach 2:
The patent introduces cleavable linker molecules as intermediaries between the antibody and cytotoxic drug. These linkers serve as temporary carriers that protect the drug during circulation and enable controlled release at the target site, reducing the need for complex direct conjugation chemistry.
2Reliability
If antibody-drug conjugates use complex chemical linkers to connect antibody and drug, then the conjugate can achieve targeted delivery, but the therapeutic index is reduced
Solution Approach 1:
The patent employs cleavable linkers that are pre-designed to break under specific physiological conditions (such as enzymatic cleavage or pH changes) at the target site. This preliminary design ensures that the cytotoxic drug remains inactive during circulation and is only activated when needed, minimizing systemic side effects while maintaining targeted delivery.
3Reliability
If ADCs use complex chemical linkers, then targeted delivery is achieved, but development time and approval process are extended
Solution Approach 1:
The patent develops universal polymer conjugate platforms that can accommodate multiple different cytotoxic drugs and antibody types through standardized conjugation chemistry. This multi-functionality allows a single platform to be used across multiple drug candidates, significantly reducing development time and enabling parallel development of multiple therapeutics.
Solution Approach 2:
The patent utilizes polymer conjugates with tunable parameters such as molecular weight, degree of substitution, and linker composition. By adjusting these parameters, developers can optimize the properties of each conjugate for its specific application without redesigning the entire system, accelerating the development and approval process.
Data Source
AI summary
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L, L1, L2, L3, M, m and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.